Introduction {#j_bjmg-2016-0037_s_001}
============

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy that ranks sixth in incidence of all cancers. The HNSCC tumors display dysregulation of cell differentiation, cell cycle control, epithelial and stromal interactions, apoptosis, angiogenesis and their associated pathways \[[@j_bjmg-2016-0037_ref_001],[@j_bjmg-2016-0037_ref_002]\]. Although its exact cause remains unclear, like most malignancies, HNSCC pathogenesis is affected by both genetic and environmental factors \[[@j_bjmg-2016-0037_ref_001]\].

Of the approximately 500,000 new cases of HNSCC each year, many occur in the oral cavity, pharynx, and larynx. Oral squamous cell carcinoma (OSCC) is the most common type of HNSCC, and China has one of the highest incidences of this cancer \[[@j_bjmg-2016-0037_ref_002]\]. Importantly, OSCC is nearly asymptomatic, which makes early diagnosis very difficult; to date, there are no accurate predictors of OSCC onset and/or progression. Therefore, identification of risk factors and high-risk populations for OSCC would enable advancements in the primary and secondary prevention of OSCC.

Cigarette smoking and alcohol consumption are known environmental risk factors for OSCC \[[@j_bjmg-2016-0037_ref_003],[@j_bjmg-2016-0037_ref_004]\]. Cigarette smoke contains polycyclic aromatic hydrocarbons, heterocyclic amines, and nitrosamines that are all carcinogenic. Long-term alcohol consumption can lead to combined overdose of reactive oxygen species (ROS) and acetaldehyde, inducing carcinogenesis. Certain enzymes have been shown to be responsible for the biotransformation of chemical carcinogens, either for activation or excretion. For example, cytochrome P4501A1, encoded by CYP1A1, is a catabolite-activating enzyme involved in the biotransformation of both tobacco and alcohol. P4501A1-mediated metabolism of tobacco combustion products, mainly polycyclic aromatic hydrocarbons, can lead to the formation of DNA adducts that contribute to tumor formation, specifically HNSCC \[[@j_bjmg-2016-0037_ref_005]\]. Other metabolizing enzymes, with variations in their respective genes, have also been previously implicated in cancer susceptibility. These include, but are not limited to, glutathione S-transferase (GST), superoxide dismutate (SOD), proteins of the SOD family, and acetaldehyde dehydrogenase (ALDH). Glutathione S-transferase plays a role in metabolizing benzo\[a\]pyrene (a tobacco-specific carcinogen), as well as other carcinogenic compounds. Superoxide dismutase, an endogenous antioxidant enzyme, has certain polymorphisms implicated in cancer susceptibility. Acetaldehyde dehydrogenase, along with alcohol dehydrogenase (ADH), metabolizes ethanol by breaking apart the molecule in order to eliminate it from the body. Genetic polymorphism in ALDH2 has been previously investigated and shown to be associated with specific cancer types \[[@j_bjmg-2016-0037_ref_005]\]. However, genes encoding these enzymes have multiple functional variants, blurring their role in OSCC susceptibility. At least one recent study found that expression of CYP1A1 and ALDH2 proteins did not affect OSCC prognosis \[[@j_bjmg-2016-0037_ref_006]\]. Thus, the specific contribution of polymorphisms in genes encoding enzymes involved in biotransformation of alcohol and tobacco components remains unclear; specifically, the role in promoting OSCC requires further study. This study reports the investigation of the association between genetic polymorphism of *CYP1A1*, *EC-SOD* (*extracellular SOD*), *GSTT1*, *GSTM1*, *ALDH2*, smoking and alcohol consumption, and susceptibility to oral squamous cell carcinoma.

Participants and Methods {#j_bjmg-2016-0037_s_002}
========================

Participants {#j_bjmg-2016-0037_s_002_s_001}
------------

This prospective study included 750 patients who were admitted to our hospital from June 2011 to May 2015. Another 750 participants who received physical examinations during the same time period were selected as healthy controls; the physical examination showed no cancer or hereditary diseases. There was no statistically significant difference in age, gender, place of origin or nationality, and the subjects were unrelated. Participant demographic data, smoking history, alcohol drinking history, occupational history and family tumor history were collected. The smoking status was evaluated using the smoking index (SI) that was the product of the daily number of cigarettes multiplied by number of years of smoking. Based on SI values, the participants were divided into the following categories: non smokers, individuals with SI ≤400, and individuals with SI 400. Alcohol consumption was evaluated with the drinking index (DI) that was the product of the daily amount of drinking (in grams) multiplied by the number of years of drinking. Based on DI values, the participants were classified as non drinkers, those with DI ≤3000, and those with DI 3000. The study was approved by the General Hospital of Daqing Oil Field, Daqing, Heilongjiang Province, People's Republic of China (PRC). Informed written consent was obtained from all participants.

Genotyping {#j_bjmg-2016-0037_s_002_s_002}
----------

From each participant, 3 mL blood was collected in vacutainers with EDTA as anticoagulant. The QIAmpDNA extraction kit (Qiagen GmbH, Hilden, Germany) was used to extract DNA from white blood cells. Extracted DNA was stored at --30 °C. Polymerase chain reaction (PCR) was used to amplify the DNA to the levels required for restriction fragment length polymorphism (RFLP) analysis. For all reactions, a total volume of 25 μL comprised 2.5 μL 10 × buffer, 2.5 μL dNTP, 20 pmol upstream primers, 20 pmol downstream primers (see below), 0.75 μL Taq DNA polymerase (all PCR reagents from Promega, Madison, WI, USA), and 100 ng template DNA. Reactions were performed on PE480 thermocycler (Perkin Elmer?, Norwalk, CT, USA), as follows: initial denaturation at 94 °C for 4 min., and 35 cycles of denaturation at 94 °C for 40 seconds, annealing at 55 °C for 40 seconds, and extension at 72 °C for 50 seconds, and final extension at 72 °C for 5 min. The PCR products were digested with restriction endonucleases as appropriate (described below). A total reaction volume of 20 μL comprised 1 ng PCR product, 2 μL 10 × NEB (New England Biolabs, Ipswich, MA, USA) reaction buffer, and 10 U endonuclease; reactions were performed at 37 °C for 3 hours. Digestion products were separated by 100V electrophoresis on a 3.0% agarose gel, for 1 hour. After 30 min. in ethidium bromide, bands were detected by ultraviolet light.

The *CYP1A1-Msp*I polymorphism was detected using the following primer sequences: upstream primer (5'-CAG TGA AGA GGT GTA GCC GCT-3'), downstream primer (5'-TAG GAG TCT TGT CTC ATG CCT-3' (synthesized by TaKaRa, Dalian, China). Restriction digestion with *Msp*I produced three genotypes: wild-type (m1/m1) with a band at 340 bp, heterozygous (m1/m2) with bands at 340, 200 and 140 bp, and homozygous mutant (m2/m2) with bands at 200 and 140 bp.

The *EC-SOD* polymorphism was detected using primer sequences as reported in a previous study \[[@j_bjmg-2016-0037_ref_007]\]: upstream primer (5'-GCA ACC AGG CCA GCG TGG AGA ACG GGA A-3'), and downstream primer 5'-CCA GAG GAG AAG CTC AAA GGC AGA-3'). The PCR product was digested with restriction endonuclease *Pau*I. Two genotypes were produced: homozygous C/C with bands at 111 and 109 bp; and heterozygous C/G with bands at 220, 111 and 109 bp.

The *GSTT1* polymorphism was detected using primer sequences according to Wilson *et al*. \[[@j_bjmg-2016-0037_ref_008]\]: upstream primer (5'-TCT CCT TAC TGG TCC TCA CAT CTC-3'), and downstream primer (5'-TCA CCG GAT CAT GGC CAG CA-3'). *GSTT1* positive \[+\] was indicated by the presence of a 480 bp fragment after PCR amplification; *GSTT1* negative \[--\] meant lack of PCR product. The control β-globin gene was detected with upstream primer (5'-CAA GAG CCA ACC ACA GGT AC-3') and downstream primer (5'-GAA GAG CCA AGG ACA GGT AC-3').

The *GSTM1* polymorphism was detected using primer sequences selected according to Nguyen *et al*. \[[@j_bjmg-2016-0037_ref_009]\]: upstream primer (5'-GAA CTC CCT GAA AAG CTA AAG C-3'), and downstream primer (5'-GTT GGG CTC AAA TAT ACG GTG G-3'). *GSTM1* positive \[+\] indicated the presence of bands at 230 and 219 bp; *GSTM1* negative \[--\] indicated the presence of only one 219 bp band. The control β-globin gene was detected with upstream primer (5'-CAA GAG CCA ACC ACA GGT AC-3'), and downstream primer (5'-GAA GAG CCA AGG ACA GGT AC-3').

The *ALDH2* polymorphism was detected using primer sequences selected according to Ishibashi *et al*. \[[@j_bjmg-2016-0037_ref_010]\]: upstream primer (5'-CCC TTT GGT GGC TAG AAG ATG-3'), and downstream primer (5'-CCA CAC TCA CAG TTT TCT CTT-3'). The PCR products were digested with the restriction endonuclease *Mbo*I. The amplified fragment was 91 bp and three genotypes could be seen after digestion: homozygous G/G with a band at 55 bp, heterozygous G/L with bands at 65 and 55 bp, and homozygous L/L with a band at 65 bp. The ALDH2 (G/L) and ALDH2 (L/L) were combined and marked as ALDH2 (non G/G) for co-analysis.

Statistical Methods {#j_bjmg-2016-0037_s_002_s_003}
-------------------

The difference in genotype distributions between the patient and control groups was determined using the χ^2^ test. A non conditional logistic regression model was used to analyze the adjusted odds ratio (OR) for risk of oral squamous cell carcinoma with different genotypes, as well as the combined effects between smoking, drinking, and genotype. The 95% confidence interval (CI) is also reported. The Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) version 11.0 was used for statistical analysis. Statistical significance was accepted at a *p* value of \<0.05.

Results {#j_bjmg-2016-0037_s_003}
=======

Oral Squamous Cell Carcinoma and Lifestyle {#j_bjmg-2016-0037_s_003_s_001}
------------------------------------------

General demographic and clinical information for participants in both groups are provided in [Table 1](#j_bjmg-2016-0037_tab_001){ref-type="table"}. There was no statistically significant difference in gender or age between case and control groups (*p* \>0.05). However, smoking and drinking were significantly more common in individuals with OSCC than in controls (*p* \<0.01).

###### 

General characteristics of healthy controls and patients with oral squamous cell carcinoma.

  -------------------------------------------------------------------------------------------------------------
  Characteristics                         Control Group\   Patient Group\   OR Value   95% CI       *p* Value
                                          (*n* = 750)      (*n* = 750)                              
  ------------------ -------------------- ---------------- ---------------- ---------- ------------ -----------
  Sex *n* (%)        males\               498 (66.40%)\    504 (67.20%)\    0.97       0.78-1.20    \>0.05
                     females              252 (33.60%)     246 (32.80%)                             

  Age                years; mean±SD       55.51±4.42       55.49±4.33       --         --           \>0.05

  Smoking status\    non-smoker\          451 (60.13%)\    265 (35.33%)\    2.76\      2.24-3.40\   \<0.01\
  *n* (%)            smoker\              299 (39.87%)\    485 (64.67%)\    6.33       4.61-8.71    \<0.01
                     SI ≤400\             202 (26.93%)\    120 (16.00%)\                            
                     SI 400               97 (12.93%)      365 (48.67%)                             

  Drinking status\   did not drink\       468 (62.40%)\    256 (34.13%)\    3.20\      2.59-3.96\   \<0.01\
  *n* (%)            did drink alcohol\   282 (37.60%)\    494 (65.87%)\    5.21       5.79-7.16    \<0.01
                     DI ≤3000\            172 (22.93%)\    114 (15.20%)\                            
                     DI 3000              110 (14.67%)     380 (50.67%)                             
  -------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval; SD: standard deviation; SI: smoking index; DI: drinking index.

Genotype Distribution {#j_bjmg-2016-0037_s_003_s_002}
---------------------

For each of the enzyme encoding genes we investigated, the distribution of genotypes, significantly differed between cases and controls (all *p* \<0.01). *CYP1A1*-*Msp*I (m2/m2), *EC-SOD* (C/G), *GSTT1* \[--\], *GSTM1* \[--\] and *ALDH2* (non G/G) genotypes were significantly more common in individuals with OSCC than in control individuals (*p* \<0.01) ([Table 2](#j_bjmg-2016-0037_tab_002){ref-type="table"}).

###### 

Distribution of *CYP1A1*-*Msp*I, *EC-SOD*, *GSTT1*, *GSTM1*, and *ALHD2* genotypes in the control and patient groups.

  ------------------------------------------------------------------------------------------------------------
  Genotype               Control Group   Patient Group   OR Value   95% CI   *p* Value                
  ---------------------- --------------- --------------- ---------- -------- ----------- ------------ --------
                         *n*             \%              *n*        \%                                

  *CYP1A1*-*Msp*I:\      593\            79.00\          463\       61.73\   1.00\       1.86-2.95    \<0.01
  m1/m1+m1/m2\           157             20.93           287        38.37    2.34                     
  m2/m2                                                                                               

  *EC-SOD*:\             605\            80.67\          380\       50.67\   1.00\       3.23-5.12    \<0.01
  C/C\                   145             19.33           370        49.27    4.06                     
  C/G                                                                                                 

  *GSTT1*:\              598\            79.73\          395\       52.67\   1.00\       2.81-43.44   \<0.01
  \[+\]\                 152             20.27           355        47.33    3.54                     
  \[--\]                                                                                              

  *GSTM1*:\              419\            55.87\          231\       30.80\   1.00\       1.95-4.47    \<0.01
  \[+\]\                 331             44.13           519        69.20    2.83                     
  \[--\]                                                                                              

  *ALHD2*: G/G non G/G   444\            55.60\          212\       30.53\   1.00\       2.97-4.57    \<0.01
                         306             44.40           538        69.47    3.68                     
  ------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Multiple Genotype Variants Distribution {#j_bjmg-2016-0037_s_003_s_003}
---------------------------------------

Because there was a significant shift of the genotype frequencies observed in individuals with OSCC compared to controls, we also examined whether OSCC patients were more likely to carry multiple variant genotypes than healthy subjects. The combined distribution of *CYP1A1*-*Msp*I (m2/ m2), *EC-SOD* (C/G), *GSTT1* \[--\], *GSTM1* \[--\] and *ALHD2* (non G/G) genotypes in both groups are provided in [Table 3](#j_bjmg-2016-0037_tab_003){ref-type="table"}. Within the patient group, the majority of individuals (90.4%) had at least two of the variants. Namely, 1.9% of individuals were positive for five of the variant genotypes, 20.8% for four genotypes, 37.1% for three genotypes, 30.7% for two genotypes, 8.5% for only one variant genotype, and only 1.1% did not have any of the variant genotypes. In contrast, in the control group, the majority of individuals had one or no variants (51.6%). Thus, the presence of two or more variants in the OSCC population was significantly more common than in controls (*p* \<0.01).

###### 

The combined distribution of *CYP1A1*-*Msp*I (m2/m2), *EC-SOD* (C/G), *GSTT1*\[--\], *GSTM1* \[--\] and *ALHD2* (non G/G) variant genotypes in the control and patient groups.

  ---------------------------------------------------------------------------------------------------
  Number of\   Control Group   Patient Group   OR Value   95% CI   *p* Value                 
  Genotypes                                                                                  
  ------------ --------------- --------------- ---------- -------- ----------- ------------- --------
  0            97              12.93           8          1.07     1.00        --            \<0.01

  1            290             38.67           64         8.53     2.68        1.23-5.78     --

  2            210             28.00           230        30.67    13.28       6.31-27.97    --

  3            90              12.00           278        37.07    37.45       17.53-80.02   --

  4            56              7.47            156        20.80    33.78       15.44-73.90   --

  5            7               0.93            14         1.86     24.25       7.61-77.27    --
  ---------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Smoking Status and Gene Polymorphisms {#j_bjmg-2016-0037_s_003_s_004}
-------------------------------------

[Table 4](#j_bjmg-2016-0037_tab_004){ref-type="table"} depicts the results of the analysis of *CYP1A1*-*Msp*I (m2/ m2), *EC-SOD* (C/G), *GSTT1* \[--\], *GSTM1* \[--\] and *ALHD2* (non G/G) variant genotype presence and smoking status. In individuals with OSCC, multiple variants and smoking were significantly more common compared to the control group; smoking in combination with multiple variant genotypes had a synergistic effect on cancer likelihood. Smokers with five variant genotypes were 32-times more likely to have OSCC.

###### 

Combined analysis of smoking status, and variant genotype distribution in relation to oral squamous cell carcinoma susceptibility.

  --------------------------------------------------------------------------------------------------------------
  Number of\   Smoking\   Control Group   Patient Group   OR Value   95% CI   *p* Value                 
  Genotypes    Status                                                                                   
  ------------ ---------- --------------- --------------- ---------- -------- ----------- ------------- --------
  0            \[--\]     92              12.27           31         4.13     1.00        --            --

  1            \[--\]     118             15.73           43         5.73     1.04        0.64-1.70     0.86

  2            \[--\]     116             15.47           90         12.00    2.22        1.44-3.44     \<0.01

  3            \[--\]     71              9.47            53         7.07     2.14        1.31-3.50     \<0.01

  4            \[--\]     40              5.33            46         6.13     3.30        1.92-5.67     \<0.01

  5            \[--\]     14              1.87            2          0.27     0.41        0.09-1.87     0.25

  0            \[+\]      37              4.93            14         1.87     0.89        0.43-1.86     0.76

  1            \[+\]      100             13.33           92         12.27    2.52        1.61-3.96     \<0.01

  2            \[+\]      78              10.40           147        19.60    2.43        1.65-3.58     \<0.01

  3            \[+\]      35              4.67            128        17.07    4.90        2.92-8.21     \<0.01

  4            \[+\]      44              5.87            81         10.80    1.60        0.91-2.80     0.10

  5            \[+\]      5               0.67            23         3.07     32.20       5.49-118-91   \<0.01
  --------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Furthermore, within the sub-population of smokers, SI was synergistic with multiple variant genotypes ([Table 5](#j_bjmg-2016-0037_tab_005){ref-type="table"}). In the patient group, the presence of multiple variant genotypes and an SI\>400 was significantly more common compared to the control group (*p* \<0.01).

###### 

Combined analysis of smoking index, and variant genotype distribution in relation to oral squamous cell carcinoma susceptibility.

  -------------------------------------------------------------------------------------------------------------
  Number of\   Smoking\   Control Group   Patient Group   OR Value   95% CI   *p* Value                
  Genotypes    Status                                                                                  
  ------------ ---------- --------------- --------------- ---------- -------- ----------- ------------ --------
  0            ≤400       45              6.00            2          0.27     1.00        --           --

  1            ≤400       54              7.20            16         2.13     0.22        0.05-1.00    0.07

  2            ≤400       45              6.00            23         3.07     0.38        0.08-1.86    0.23

  3            ≤400       33              4.40            44         5.87     1.00        1.00-0.21    1.00

  4            ≤400       23              3.07            32         4.27     1.04        0.21-5.12    0.96

  5            ≤400       2               0.27            3          0.40     1.12        0.11-11.60   0.92

  0            400        3               0.40            4          0.53     1.82        0.51-2.85    0.49

  1            400        45              6.00            24         3.20     1.80        0.85-3.80    0.12

  2            400        28              3.73            123        16.40    8.60        4.50-16.44   \<0.01

  3            400        11              1.47            153        20.40    10.43       4.88-22.31   \<0.01

  4            400        9               1.20            57         7.60     4.55        1.88-11.02   \<0.01

  5            400        1               0.13            4          0.53     2.67        0.16-45.14   0.50
  -------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Drinking Status and Gene Polymorphisms {#j_bjmg-2016-0037_s_003_s_005}
--------------------------------------

A similar analysis was applied to *CYP1A1*-*Msp*I (m2/m2), *EC-SOD* (C/G), *GSTT1* \[--\], *GSTM1* \[--\] and *ALHD2* (non G/G) variant genotypes and alcohol consumption ([Table 6](#j_bjmg-2016-0037_tab_006){ref-type="table"}). The presence of multiple variants and alcohol consumption was significantly more common in patients compared to the control group; furthermore, as with smoking, the drinking behavior and combined variant genotypes had a synergistic effect on the likelihood of cancer.

###### 

Combined analysis of drinking status, and variant genotype distribution in relation to oral squamous cell carcinoma susceptibility.

  --------------------------------------------------------------------------------------------------------------
  Number of\   Drinking\   Control Group   Patient Group   OR Value   95% CI   *p* Value                
  Genotypes    Status                                                                                   
  ------------ ----------- --------------- --------------- ---------- -------- ----------- ------------ --------
  0            \[--\]      100             13.33           27         3.60     1.00        --           --

  1            \[--\]      166             22.13           42         5.60     0.41        0.21-0.80    0.01

  2            \[--\]      105             14.00           77         10.27    1.18        0.61-2.28    0.62

  3            \[--\]      51              6.80            65         8.67     2.05        1.03-4.11    0.04

  4            \[--\]      43              5.73            43         5.73     1.61        0.78-3.32    0.20

  5            \[--\]      3               0.40            2          0.27     1.07        0.16-7.06    0.94

  0            \[+\]       29              3.87            18         2.40     0.44        0.21-0.90    0.03

  1            \[+\]       52              6.93            93         12.40    7.07        4.38-11.42   \<0.01

  2            \[+\]       89              11.87           160        21.33    2.45        1.66-3.63    \<0.01

  3            \[+\]       55              7.33            116        15.47    1.66        1.02-2.69    0.04

  4            \[+\]       41              5.47            84         11.20    2.05        1.67-3.60    0.01

  5            \[+\]       16              2.13            23         3.07     2.16        0.32-14.41   0.43
  --------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

The synergistic effect of the DI and combined expression of variant genotypes is depicted in [Table 7](#j_bjmg-2016-0037_tab_007){ref-type="table"}. In the patient group, the presence of multiple variants and a DI \>3000 was significantly more common compared to the control group (*p* \<0.01).

###### 

Combined analysis of drinking index, and variant genotype distribution in relation to oral squamous cell carcinoma susceptibility.

  --------------------------------------------------------------------------------------------------------------
  Number of\   Drinking\   Control Group   Patient Group   OR Value   95% CI   *p* Value                
  Genotypes    Index                                                                                    
  ------------ ----------- --------------- --------------- ---------- -------- ----------- ------------ --------
  0            ≤3000       21              2.80            3          0.40     1.00        --           --

  1            ≤3000       47              6.27            15         2.00     0.80        0.01-077     0.03

  2            ≤3000       49              6.53            26         3.47     0.13        0.01-1.25    0.08

  3            ≤3000       36              4.80            38         5.07     0.26        0.03-2.47    3.79

  4            ≤3000       16              2.13            28         3.73     0.44        0.05-4.26    0.48

  5            ≤3000       3               0.40            4          0.53     0.33        0.02-4.74    0.42

  0            3000        1               0.13            4          0.53     2.96        0.55-6.28    0.08

  1            3000        24              3.20            44         5.87     5.74        2.67-12.35   \<0.01

  2            3000        39              5.20            122        16.27    5.90        3.27-10.71   \<0.01

  3            3000        30              4.00            138        18.40    4.36        2.38-7.97    \<0.01

  4            3000        14              1.87            54         7.20     2.20        0.94-5.16    0.07

  5            3000        2               0.27            18         2.40     6.75        0.83-54.66   0.07
  --------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Analysis of Combined Smoking/Drinking Status and Gene Polymorphisms {#j_bjmg-2016-0037_s_003_s_006}
-------------------------------------------------------------------

[Table 8](#j_bjmg-2016-0037_tab_008){ref-type="table"} displays the results of the analysis of the presence of variant genotypes combined with smoking and drinking status. In the patient group, there were significantly more patients who had multiple variants and were positive for both smoking and drinking history as compared to the control group.

###### 

Combined analysis of smoking and drinking status, and variant genotype distribution in relation to oral squamous cell carcinoma susceptibility.

  -------------------------------------------------------------------------------------------------------------
  Number of\   Smoking\   Drinking\   Controls   Patients   OR\     95% CI   *p* Value                 
  Genotypes    Status     Status                            Value                                      
  ------------ ---------- ----------- ---------- ---------- ------- -------- ----------- ------------- --------
  0            \[--\]     \[--\]      68         9.07       15      2.00     1.00        --            --

  1            \[--\]     \[--\]      82         10.93      12      1.60     1.04        0.64-1.70     0.86

  2            \[--\]     \[--\]      48         6.40       42      5.60     2.22        1.44-3.44     \<0.01

  3            \[--\]     \[--\]      27         3.60       21      2.80     2.14        1.31-3.50     \<0.01

  4            \[--\]     \[--\]      18         2.40       18      2.40     3.30        1.91-5.67     \<0.01

  5            \[--\]     \[--\]      1          0.13       1       0.13     0.41        0.09-1.87     0.25

  0            \[--\]     \[+\]       24         3.20       16      2.13     1.91        0.31-11.81    0.48

  1            \[--\]     \[+\]       36         4.80       31      4.13     7.07        4.38-11.42    \<0.01

  2            \[--\]     \[+\]       68         9.07       48      6.40     2.45        1.66-3.63     \<0.01

  3            \[--\]     \[+\]       44         5.87       32      4.27     1.66        1.02-2.69     0.04

  4            \[--\]     \[+\]       22         2.93       28      3.73     2.05        1.17-3.60     0.01

  5            \[--\]     \[+\]       13         1.73       1       0.13     2.16        0.32-14.40    0.43

  0            \[+\]      \[--\]      32         4.27       12      1.60     0.86        0.16-4.63     0.87

  1            \[+\]      \[--\]      84         11.20      30      4.00     2.53        1.51-3.96     \<0.01

  2            \[+\]      \[--\]      57         7.60       35      4.67     2.43        1.65-3.58     \<0.01

  3            \[+\]      \[--\]      24         3.20       44      5.87     4.90        2.92-8.21     \<0.01

  4            \[+\]      \[--\]      25         3.33       25      3.33     1.60        0.91-2.80     0.10

  5            \[+\]      \[--\]      2          0.27       1       0.13     32.20       5.49-188.91   \<0.01

  0            \[+\]      \[+\]       5          0.67       2       0.27     3.45        1.62-5.41     \<0.01

  1            \[+\]      \[+\]       16         2.13       62      8.27     10.36       6.53-16.44    \<0.01

  2            \[+\]      \[+\]       21         2.80       112     14.93    6.20        4.12-9.33     \<0.01

  3            \[+\]      \[+\]       11         1.47       84      11.20    5.23        3.33-820      \<0.01

  4            \[+\]      \[+\]       19         2.53       56      7.47     4.19        2.67-6.58     \<0.01

  5            \[+\]      \[+\]       3          0.40       22      2.93     13.26       4.09-42.97    \<0.01
  -------------------------------------------------------------------------------------------------------------

OR: odds ratio; 95% CI: 95% confidence interval.

Discussion {#j_bjmg-2016-0037_s_004}
==========

The pathogenesis of OSCC is complex, involving combined action of a variety of environmental and genetic factors \[[@j_bjmg-2016-0037_ref_011]-[@j_bjmg-2016-0037_ref_013]\]. Smoking and drinking are the main risk factors for OSCC \[[@j_bjmg-2016-0037_ref_014],[@j_bjmg-2016-0037_ref_015]\]. Our findings confirm that smoking and drinking were significantly more frequent in individuals with OSCC than in the control individuals. Heavy cigarette and alcohol consumption were also significantly higher in the OSCC group compared to the control group.

The CYP1A1 is a member of the cytochrome P450 family involved in the metabolism of exogenous materials, encoding aryl hydrocarbon hydrolase (AHH), and activating polycyclic aromatic hydrocarbon and aromatic amine \[[@j_bjmg-2016-0037_ref_016]\]. Our results showed that the distribution of genotypes for *CYP1A1*-*Msp*I was significantly different between the patient group and the control group, and that the *CYP1A1*-*Msp*I (m2/m2) genotype may increase susceptibility to OSCC. This finding, aligned with prior studies, shed light on the involvement of the *CYP1A1*-*Msp*I polymorphism in carcinogenesis through modified enzymatic activity \[[@j_bjmg-2016-0037_ref_016]\]. Our results also confirmed the results of a meta-analysis which found that *CYP1A1*-*Msp*I increased the odds of OSCC, specifically among Asian populations \[[@j_bjmg-2016-0037_ref_030]\].

Superoxide dismutase is generally considered as the first line antioxidative defense in the body \[[@j_bjmg-2016-0037_ref_017]\]. This enzyme can be highly effective against ROS to protect the cells and tissues from oxidative stress \[[@j_bjmg-2016-0037_ref_018]\]. The SOD dysregulation is correlated with growth of human malignant tumors \[[@j_bjmg-2016-0037_ref_019],[@j_bjmg-2016-0037_ref_020]\]. Further, EC-SOD appears to be important for tumor formation \[[@j_bjmg-2016-0037_ref_021]-[@j_bjmg-2016-0037_ref_023]\], and is correlated with OSCC \[[@j_bjmg-2016-0037_ref_024]\]. Our study mirrored the earlier studies that indicated EC-SOD association with OSCC and showed a significant difference in distribution of EC-SOD genotypes between the patient and control groups \[[@j_bjmg-2016-0037_ref_024]\].

The GST polymorphisms are also correlated with cancer susceptibility. Glutathione S-transferase can catalyze the binding of electrophilic carcinogens and glutathione, to metabolize compounds that are easily soluble in water and excrete them. *GSTM1*/*GSTT1* has been previously associated with susceptibility to oral carcinomas \[[@j_bjmg-2016-0037_ref_025],[@j_bjmg-2016-0037_ref_031]\]. Our study confirmed that *GSTM1*\[--\]/GSTT1\[--\] genotypes are correlated with susceptibility to OSCC.

Animal studies have found that the *in vivo* metabolite of ethanol, acetaldehyde, has significant carcinogenic effects \[[@j_bjmg-2016-0037_ref_026],[@j_bjmg-2016-0037_ref_027]\], and ALDH2 is the main enzyme to metabolize acetaldehyde in the liver. Furthermore, *ALDH2* gene polymorphism is correlated with a variety of tumors \[[@j_bjmg-2016-0037_ref_028]-[@j_bjmg-2016-0037_ref_030],[@j_bjmg-2016-0037_ref_032]\]. Our study confirmed the correlation between *ALDH2* (non G/G) genotypes and increased susceptibility to OSCC.

Interestingly, our study also found significant differences in the prevalence of combined *CYP1A1*-*Msp*I (m2/ m2), *EC-SOD* (C/G), *GSTT1* \[--\], *GSTM1* \[--\] and *ALHD2* (non G/G) variant genotypes between the patient and control groups. In the patient group, the percentage of patients with a combination of variant genotypes (more than two genotypes) was significantly higher than that of the control group; the relative risks of OSCC in such patients were significantly increased. Previous studies have shown that OSCC patients are more likely to carry multiple variants and have a history of smoking or drinking; the interaction of two or more of these factors enhances risk \[[@j_bjmg-2016-0037_ref_003],[@j_bjmg-2016-0037_ref_005],[@j_bjmg-2016-0037_ref_029],[@j_bjmg-2016-0037_ref_030],[@j_bjmg-2016-0037_ref_032]\]. Our simultaneous analyses confirmed these previous results, as individuals with both multiple variant genotypes and a smoking and drinking history exhibited a significantly higher risk of OSCC. Therefore, OSCC risk increases with the increasing amount and period of smoking and drinking.

Further investigations and studies of the effects of these gene and environmental interactions is paramount to an earlier diagnosis of OSCC. More studies of non Asian populations is another avenue of research worth undertaking.
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